Modular analytic p biochemistry analyzer

Plasma and urine sodium, potassium and lithium concentrations were measured by flame photometry (Micronal, B262, São Paulo, Brazil), while creatinine concentrations were determined spectrophotometrically (Instruments Laboratory, Genesys V, USA). The Glucose Analyzer YSI 2300 measured plasma glucose. Plasma concentrations of insulin and C-peptide were measured by immunoassay (Millipore, Billerica, USA, with sensibility of 1μU/ml; and 0,05 ng/ml, respectively). The HDL and LDL-cholesterol and, Triglyceride levels were also measured using enzyme immunoassay kits with a Modular Analytic P Biochemistry Analyzer (Roche®) according to the manufacturers' protocols. The cytokines were measured by immunoassay (adiponectin, Millipore, Billerica, USA, sensibility 0,155 ng/ml; IL-6 R&D SYSTEMS®, Minneapolis, USA, sensibility 0,039 pg/ml; leptin Millipore, Billerica, USA, sensibility 0,195 ng/ml; TNF-α R&D SYSTEMS®, Minneapolis, USA; CRP DIAsource ImmunoAssays S.A, Louvain-la-Neuv, Belgium, sensibility 10 ng/ml).

Plasma and urine sodium, potassium, and lithium concentrations were measured by flame photometry (Micronal, B262, São Paulo, Brazil), while creatinine concentrations were determined spectrophotometrically (Instruments Laboratory, Genesys V, USA). Glucose from whole blood was measured with a glucometer MediSense/Optium, Abbott. Plasma concentrations of insulin were measured by immunoassay (Millipore, Billerica, USA, with sensibility of 0.05 ng/mL). The plasma samples for urea, albumin, globulin, total protein, chloride, magnesium, calcium, phosphorus, HDL cholesterol, LDL cholesterol, and triglyceride levels were also collected on the 8th week posttreatment in ND and HFD and measured by a Modular Analytic P Biochemistry Analyzer (Roche^®) according to the manufacturers’ protocols for clinical and immunochemistry assays.